We serve Chemical Name:2-(aminomethyl)-4,6-dibromophenol CAS:5428-91-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(aminomethyl)-4,6-dibromophenol
CAS.NO:5428-91-1
Synonyms:2-Aminomethyl-4,6-dibrom-phenol;2-aminomethyl-4,6-dibromo-phenol;3.5-Dibrom-2-oxy-benzylamin
Molecular Formula:C7H7Br2NO
Molecular Weight:280.94500
HS Code:2922299090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:323.3ºC at 760mmHg
Density:2.003g/cm3
Index of Refraction:1.663
PSA:46.25000
Exact Mass:278.88900
LogP:3.07620
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-Aminomethyl-4,6-dibrom-phenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3.5-Dibrom-2-oxy-benzylamin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-aminomethyl-4,6-dibromo-phenol Use and application,3.5-Dibrom-2-oxy-benzylamin technical grade,usp/ep/jp grade.
Related News: Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. 2-(aminomethyl)-4,6-dibromophenol manufacturer European companies are the main suppliers of specialty APIs, but due to environmental and cost pressures, APIs have begun to shift to the Asian market. 2-(aminomethyl)-4,6-dibromophenol supplier It is delivered to hospitals and pharmacies until it reaches the patient. 2-(aminomethyl)-4,6-dibromophenol vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 2-(aminomethyl)-4,6-dibromophenol factory Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical.
